Literature DB >> 26205546

Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis.

Allen D Seftel1, Martin Kathrins2, Craig Niederberger2.   

Abstract

"Testosterone Therapy in Men With Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline" (Guidelines), published in 2010, serves as an important guide for the treatment of hypogonadal men. Using the Guidelines as a basis, we searched for the most recent level 1 evidence that continues to support the recommendations or provide an impetus to modify all or some of them. We performed a systematic analysis with a PubMed query from January 1, 2010, through March 2, 2015, using the following key words: testosterone/deficiency, testosterone/therapeutic use, cardiovascular, morbidity, mortality, screening, sexual function, lower urinary tract symptoms, obstructive sleep apnea, prostate cancer, fertility, bone mineral density, osteoporosis, quality of life, cognitive, erectile dysfunction, and adverse effects. We identified 17 trials representing level 1 evidence that specifically addressed recommendations made in the Guidelines. Trials examining outcomes of testosterone replacement therapy in men with severe lower urinary tract symptoms and untreated obstructive sleep apnea were identified, potentially refuting the current dogma against treatment in the setting of these conditions. Hypogonadal men with type 2 diabetes mellitus and metabolic syndrome were examined in several trials, demonstrating the beneficial effects of therapy on sexual function and insulin sensitivity. Several trials served as reinforcing evidence for the beneficial effects of testosterone therapy on osteoporosis, muscle strength, and symptoms of frailty. As in the Guidelines, inconsistent effects on quality of life, well-being, and erectile function were also noted in publications. Despite controversies surrounding cardiovascular morbidity and treatment in the setting of prostate cancer, no studies examining these issues as primary end points were identified. The low number of eligible studies since 2010 is a limitation of this analysis.
Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26205546     DOI: 10.1016/j.mayocp.2015.06.002

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  26 in total

Review 1.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

Review 2.  Opioid-Induced Androgen Deficiency (OPIAD): Diagnosis, Management, and Literature Review.

Authors:  Timothy K O'Rourke; Matthew S Wosnitzer
Journal:  Curr Urol Rep       Date:  2016-10       Impact factor: 3.092

Review 3.  Leydig cell stem cells: Identification, proliferation and differentiation.

Authors:  Haolin Chen; Yiyan Wang; Renshan Ge; Barry R Zirkin
Journal:  Mol Cell Endocrinol       Date:  2016-10-12       Impact factor: 4.102

4.  Inflammation, Immune Activation, Immunosenescence, and Hormonal Biomarkers in the Frailty-Related Phenotype of Men With or at Risk for HIV Infection.

Authors:  Kristine M Erlandson; Derek K Ng; Lisa P Jacobson; Joseph B Margolick; Adrian S Dobs; Frank J Palella; Jordan E Lake; Hanhvy Bui; Lawrence Kingsley; Todd T Brown
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

5.  Transplantation of alginate-encapsulated seminiferous tubules and interstitial tissue into adult rats: Leydig stem cell differentiation in vivo?

Authors:  Haolin Chen; Shiying Jin; Shengsong Huang; Janet Folmer; June Liu; Renshan Ge; Barry R Zirkin
Journal:  Mol Cell Endocrinol       Date:  2016-08-31       Impact factor: 4.102

Review 6.  Erectile dysfunction and diabetes: A melting pot of circumstances and treatments.

Authors:  Giuseppe Defeudis; Rossella Mazzilli; Marta Tenuta; Giovanni Rossini; Virginia Zamponi; Soraya Olana; Antongiulio Faggiano; Paolo Pozzilli; Andrea M Isidori; Daniele Gianfrilli
Journal:  Diabetes Metab Res Rev       Date:  2021-09-21       Impact factor: 8.128

7.  Association of Urinary Phthalate Metabolites With Erectile Dysfunction in Racial and Ethnic Groups in the National Health and Nutrition Examination Survey 2001-2004.

Authors:  David S Lopez; Shailesh Advani; Konstantinos K Tsilidis; Run Wang; Jacques Baillargeon; Adrian Dobs; Elaine Symanski; Steven Canfield
Journal:  Am J Mens Health       Date:  2016-04-01

Review 8.  [The "obese" and "old" male patient in dermatological practice. When should hypogonadism be considered?].

Authors:  D Varwig-Janßen; F Ochsendorf
Journal:  Hautarzt       Date:  2015-12       Impact factor: 0.751

Review 9.  Environmental Factors-Induced Oxidative Stress: Hormonal and Molecular Pathway Disruptions in Hypogonadism and Erectile Dysfunction.

Authors:  Shubhadeep Roychoudhury; Saptaparna Chakraborty; Arun Paul Choudhury; Anandan Das; Niraj Kumar Jha; Petr Slama; Monika Nath; Peter Massanyi; Janne Ruokolainen; Kavindra Kumar Kesari
Journal:  Antioxidants (Basel)       Date:  2021-05-24

Review 10.  Stem Leydig Cells in the Adult Testis: Characterization, Regulation and Potential Applications.

Authors:  Panpan Chen; Barry R Zirkin; Haolin Chen
Journal:  Endocr Rev       Date:  2020-02-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.